Fenbendazole — Research Protocol
⚠️ RESEARCH SUMMARY — NOT A TREATMENT PROTOCOL. Discuss all findings with your healthcare provider.
Fenbendazole research for cancer is based on case reports and preclinical data. No FDA-approved oncology dosing exists for humans. Dosing regimens in published literature vary significantly. This page summarizes published research protocols. It is not a guide for self-treatment. Discuss any treatment decisions with your physician.
Research Dosing (from Published Studies)
| Context | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Tippens case report (single patient) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited case report | Single case report with concurrent vitamin E, curcumin, and CBD. Uncontrolled. This is anecdotal data from one individual and cannot be generalized. |
| Preclinical (mouse xenograft models) | 1 mg/mouse (~50 mg/kg in mice) | Oral gavage | Every other day | Dogra et al. 2018, Sci Rep. Tumor growth inhibition reported in multiple xenograft models. Animal data; not directly applicable to humans. |
| Veterinary anthelmintic (approved use) | Veterinary dose per label | Oral | Per veterinary label | FDA-approved veterinary dose. Safety profile well-established in animals. Fenbendazole is NOT approved for human use. |
Pharmacokinetics
Poor oral bioavailability (~10%) in humans. Enhanced by high-fat meals (2-3x increase). Metabolized by CYP enzymes to oxfendazole (active metabolite) and fenbendazole sulfone. Half-life ~8-10 hours.
Safety Profile
Veterinary safety data is extensive. Human data is limited. Reported side effects from case reports: mild GI discomfort, transient liver enzyme elevation. Mebendazole (closely related) has more human safety data and is FDA-approved for human use.
Contraindications
- Not approved for human use — informed consent required
- Hepatic impairment (liver enzyme monitoring essential)
- Pregnancy (teratogenic in animal studies)
- Concurrent use of other hepatotoxic drugs
Monitoring Parameters
- Liver function tests (weekly for first month, then monthly)
- CBC with differential (monthly)
- Imaging per oncology standard of care
- Patient symptom diary